Methods and compositions for wound healing

• US 10,406,174 B2
• Filed: 10/03/2016
• Issued: 09/10/2019
• Est. Priority Date: 11/15/2006
• Status: Active Grant

• Current Assignee: OcuNexus Therapeutics, Inc.
• Original Assignee: OcuNexus Therapeutics, Inc.
• Inventors: Green, Colin R., Duft, Bradford J., Becker, David L.
• Primary Examiner(s): McGarry, Sean
• Application Number:
  US15/284,389
• Publication Number:
  US 20170296571A1
• Time in Patent Office: 1,072 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 35/33 Fibroblasts
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 38/1754 Insulin-like growth factor binding proteins
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/18 Antioxidants, e.g. antiradicals preparations for protection against sunlight A61Q17/00
• CPC Class Codes: A61P 23/02 Local anaesthetics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/02 Local antiseptics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 : Antisense

Abstract

Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.

Claims

1. A method for promoting or improving healing of optic nerve or eye tissue in a subject, comprising administering to the subject an anti-connexin agent simultaneously with, separately from or sequentially with a medicament comprising a therapeutically effective amount of an antagonist of VEGF, wherein the connexin agent is an anti-connexin 43 polynucleotide or an anti-connexin 43 peptide or peptidomimetic.

2. A method according to claim 1, wherein the anti-connexin agent and the VEGF antagonist are administered simultaneously.

3. A method according to claim 1, wherein the anti-connexin agent and the VEGF antagonist are not administered simultaneously.

4. A method according to claim 1, wherein the anti-connexin agent and the VEGF antagonist are administered sequentially.

5. A method according to claim 1, wherein the anti-connexin agent is administered first.

6. A method according to claim 1, wherein the VEGF antagonist is administered first.

7. The method according to any one of claim 1, or 2-5, wherein the anti-connexin agent is formulated in a matrix.

16. The method according to any one of claim 1, or 2-5, wherein the anti-connexin agent is formulated in a delayed release preparation, a slow release preparation, an extended release preparation, a controlled release preparation.

8. A method for promoting or improving healing of eye tissue in a subject, comprising administering to the subject an anti-connexin 43 peptide or peptidomimetic simultaneously with, separately from or sequentially with a medicament comprising a therapeutically effective amount of an antagonist of VEGF.

9. A method according to claim 8, wherein the antagonist of VEGF is an antagonist of VEGF-A.

10. A method according to claim 8, wherein the anti-connexin 43 peptide or peptidomimetic is from 8 to about 15 amino acids and comprises SRPTEKT (SEQ ID NO:

35).

11. A method according to claim 8, wherein the anti-connexin 43 peptide or peptidomimetic is from 11 to about 13 amino acids and comprises SRPTEKT (SEQ ID NO:

35).

12. A method according to claim 10, wherein the anti-connexin 43 peptide or peptidomimetic is VDCFLSRPTEKT (SEQ.ID.NO:

18).

13. A method according to claim 10, wherein the anti-connexin 43 peptide or peptidomimetic is SRPTEKTIFII (SEQ.ID.NO:

19).

14. A method according to claim 11, wherein the anti-connexin 43 peptide or peptidomimetic is VDCFLSRPTEKT (SEQ.ID.NO:

18).

15. A method according to claim 11, wherein the anti-connexin 43 peptide or peptidomimetic is SRPTEKTIFII (SEQ.ID.NO:

19).

17. The method according to any one of claims 8-13, 14, or, 15 wherein the anti-connexin agent is formulated in a matrix.

18. The method according to any one of claims 8-13, 14, or, 15 wherein the anti-connexin agent is formulated in a delayed release preparation, a slow release preparation, an extended release preparation, a controlled release preparation.